title: In vitro hematopoietic differentiation of human embryonic stem cells induced by co-culture with human bone marrow stromal cells and low dose cytokines.
abstract: Human embryonic stem (hES) cells randomly differentiate into multiple cell types during embryoid body (EB) development and limited studies have focused on directed hematopoietic differentiation. Here, we report that the treatment of hES cells during EBs development with a combination of low dose hematopoietic cytokines, including stem cell factor (SCF), Flt-3 ligand, vascular endothelial growth factor (VEGF) and human bone marrow stromal cells (hBMSCs), generated cell clusters that contained 8.81% KDR-positive hemangioblasts, 9.94% CD34-positive hematopoietic stem cells and 25.7% CD45-positive mature hematopoietic cells, and expressed hematopoietic genes such as KDR, stem cell leukemia (scl) and runt-related transcription factor 1 (Runx1). We provide the first evidence for the role of the cytokine-hBMSCs combination in promoting hematopoietic differentiation of hES cells, and thus provide the potential for generation of hematopoietic cells, as well as for understanding early developmental events that govern the initiation of hematopoiesis in humans.
authors.affiliation: National Stem Cell Engineering Centre, Institute of Human Reproductive and Stem Cell Engineering, Central South University, Changsha, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Hui-Ping
authors.initials: HP
authors.lastname: Zhao
authors.forename: Ge
authors.initials: G
authors.lastname: Lin
authors.forename: Chang-Qing
authors.initials: CQ
authors.lastname: Xie
authors.forename: Dong-Song
authors.initials: DS
authors.lastname: Nie
authors.forename: Qi-Ru
authors.initials: QR
authors.lastname: Wang
authors.forename: Guang-Xiu
authors.initials: GX
authors.lastname: Lu
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D051792:Basic Helix-Loop-Helix Proteins; D015415:Biomarkers / Q000378:metabolism; D001854:Bone Marrow Cells / Q000502:physiology*; D002454:Cell Differentiation / Q000187:drug effects*; D019070:Cell Lineage; D018920:Coculture Techniques; D003114:Colony-Forming Units Assay; D050676:Core Binding Factor Alpha 2 Subunit; D016207:Cytokines / Q000494:pharmacology*; D004268:DNA-Binding Proteins / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004622:Embryo, Mammalian / Q000166:cytology*; D005333:Fetus; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D019089:Stem Cell Factor / Q000378:metabolism; D013234:Stem Cells / Q000166:cytology*; D017154:Stromal Cells / Q000502:physiology*; D000073942:T-Cell Acute Lymphocytic Leukemia Protein 1; D014157:Transcription Factors / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D051792:Basic Helix-Loop-Helix Proteins; D015415:Biomarkers; D050676:Core Binding Factor Alpha 2 Subunit; D016207:Cytokines; D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; D019089:Stem Cell Factor; D000073942:T-Cell Acute Lymphocytic Leukemia Protein 1; D014157:Transcription Factors; D042461:Vascular Endothelial Growth Factor A; C493728:RUNX1 protein, human; C467484:VEGFA protein, human; C067143:TAL1 protein, human